BR0112280A - Nova utilização para deferiprona - Google Patents

Nova utilização para deferiprona

Info

Publication number
BR0112280A
BR0112280A BR0112280-0A BR0112280A BR0112280A BR 0112280 A BR0112280 A BR 0112280A BR 0112280 A BR0112280 A BR 0112280A BR 0112280 A BR0112280 A BR 0112280A
Authority
BR
Brazil
Prior art keywords
deferiprone
patient
new use
cardiac disease
induced cardiac
Prior art date
Application number
BR0112280-0A
Other languages
English (en)
Inventor
Michael Spino
Antonia Piga
Original Assignee
Apotex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4166629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0112280(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotex Inc filed Critical Apotex Inc
Publication of BR0112280A publication Critical patent/BR0112280A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"NOVA UTILIZAçãO PARA DEFERIPRONA". Método de tratamento de doenças cardíacas induzidas por ferro em pacientes com sobrecarga de ferro, tais como em talassemia ou similares, que compreende a administração ao paciente de quantidade terapeuticamente eficaz de deferiprona ou um de seus sais fisiologicamente aceitáveis suficiente para o tratamento de doenças cardíacas induzidas por ferro, normalmente associadas à sobrecarga de ferro.
BR0112280-0A 2000-06-30 2001-06-28 Nova utilização para deferiprona BR0112280A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2313270A CA2313270C (en) 2000-06-30 2000-06-30 Use of deferiprone in treating and preventing iron-induced cardiac disease
PCT/CA2001/000956 WO2002002114A1 (en) 2000-06-30 2001-06-28 A new use for deferiprone

Publications (1)

Publication Number Publication Date
BR0112280A true BR0112280A (pt) 2003-05-13

Family

ID=4166629

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112280-0A BR0112280A (pt) 2000-06-30 2001-06-28 Nova utilização para deferiprona

Country Status (16)

Country Link
US (2) US7049328B2 (pt)
EP (1) EP1294379B1 (pt)
CN (3) CN101933924A (pt)
AT (1) ATE427107T1 (pt)
AU (2) AU2001270402B9 (pt)
BR (1) BR0112280A (pt)
CA (1) CA2313270C (pt)
CY (1) CY1109191T1 (pt)
DE (1) DE60138189D1 (pt)
DK (1) DK1294379T3 (pt)
ES (1) ES2324978T3 (pt)
HK (1) HK1043316A1 (pt)
IL (2) IL153733A0 (pt)
PT (1) PT1294379E (pt)
WO (1) WO2002002114A1 (pt)
ZA (1) ZA200109322B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008137604A (ru) * 2006-02-22 2010-03-27 Арнольд МЮННИК (FR) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа
CN102964296B (zh) 2007-03-28 2015-03-25 阿普泰克斯科技公司 去铁酮的氟化衍生物
AU2008355464C1 (en) 2008-04-25 2014-11-20 Chiesi Farmaceutici S.P.A. Liquid formulation for deferiprone with palatable taste
PT2448922E (pt) 2009-07-03 2014-12-02 Apotex Technologies Inc Derivados fluorados de 3-hidroxipiridina-4-onas
US9849146B2 (en) 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
US8603814B2 (en) * 2009-07-20 2013-12-10 Rutgers The State University Of New Jersey Method of inhibiting nonsense-mediated mRNA decay
BR112014012054A2 (pt) * 2011-11-18 2017-05-30 Apotex Tech Inc métodos de tratamento com deferiprona
WO2016029158A2 (en) * 2014-08-21 2016-02-25 Collaborative Medicinal Development Llc Compositions and methods for extending lifespan
KR20240137106A (ko) * 2016-08-05 2024-09-19 아브페로 파마슈티칼스, 인크. 금속-매개 상태를 치료하기 위한 투여 요법
CN106983746A (zh) * 2017-03-23 2017-07-28 武汉联合药业有限责任公司 一种药物组合物及其用途
MD3684344T2 (ro) 2017-10-25 2025-09-30 Chiesi Farm Spa Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
EP3999059A1 (en) * 2019-07-19 2022-05-25 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt)
CN114217071B (zh) * 2021-12-01 2023-11-14 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法铁蛋白胶乳比浊检测试剂盒
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
WO2023198640A1 (en) 2022-04-11 2023-10-19 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
CN115429881A (zh) * 2022-09-02 2022-12-06 中国医学科学院基础医学研究所 铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2118176B (en) * 1982-03-24 1985-12-04 Nat Res Dev Pharmaceutical compositions
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor

Also Published As

Publication number Publication date
CN101380322B (zh) 2015-06-24
CN101380322A (zh) 2009-03-11
IL153733A (en) 2010-04-29
PT1294379E (pt) 2009-05-04
ES2324978T3 (es) 2009-08-21
IL153733A0 (en) 2003-07-06
HK1043316A1 (zh) 2002-09-13
US20030158234A1 (en) 2003-08-21
EP1294379B1 (en) 2009-04-01
HK1130422A1 (en) 2009-12-31
DK1294379T3 (da) 2009-06-02
AU7040201A (en) 2002-01-14
WO2002002114A1 (en) 2002-01-10
CY1109191T1 (el) 2014-07-02
DE60138189D1 (de) 2009-05-14
US20060122273A1 (en) 2006-06-08
CN101933924A (zh) 2011-01-05
ZA200109322B (en) 2002-10-21
CA2313270C (en) 2011-09-13
AU2001270402B9 (en) 2006-03-02
CA2313270A1 (en) 2001-12-30
CN1331971A (zh) 2002-01-23
AU2001270402B2 (en) 2006-02-02
US7049328B2 (en) 2006-05-23
EP1294379A1 (en) 2003-03-26
ATE427107T1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
GB0225474D0 (en) Therapeutic agents
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
JP2003528919A5 (pt)
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
EP1270000A3 (en) Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
BR0316059A (pt) Uso de fosinopril para reduzir eventos cardiovasculares em pacientes de diálise
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
SI1553938T1 (sl) Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
ECSP993206A (es) Metodo para mejorar la farmacocinetica del tipranavir
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.